New tuberculosis drug development: targeting the shikimate pathway.

Area of Science:

• Microbiology
• Drug Discovery
• Biochemistry

Background:

• Tuberculosis (TB) is a major global health concern causing significant morbidity and mortality.
• No new TB drugs have been approved in the last four decades, highlighting an urgent need for novel therapeutics.
• Drug resistance and HIV co-infection complicate TB treatment, necessitating innovative treatment strategies.

Purpose of the Study:

• To review the potential of the shikimate pathway as a source of new drug targets for tuberculosis.
• To address the critical need for novel anti-TB agents due to treatment challenges and resistance.
• To explore the role of persister bacteria biology in TB treatment failure.

Main Methods:

• Review of current literature on molecular tools and drug targets in TB research.
• Focus on the enzymes within the shikimate pathway.
• Analysis of the biological relevance of shikimate pathway enzymes in Mycobacterium tuberculosis.

Main Results:

• The shikimate pathway presents a promising avenue for identifying new anti-TB drug targets.
• Enzymes within this pathway are essential for the survival of Mycobacterium tuberculosis.
• Shikimate kinase has been identified as a particularly attractive target.

Conclusions:

• Targeting enzymes in the shikimate pathway, especially shikimate kinase, could lead to the development of effective new TB drugs.
• This approach may also contribute to the development of novel TB vaccines.
• Further research into the shikimate pathway is crucial for advancing TB treatment and control efforts.